Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for Urinary Supersaturations in Kidney Stone Formers
NCT04911660Phase 2Completed
- Sponsor
- Insel Gruppe
- Start
- Aug 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in nephrolithiasis comparing Empagliflozin First with Placebo First (2 arms). Primary endpoints: Calcium Oxalate Supersaturation in Urine at 14 days, Calcium Phosphate Supersaturation in Urine at 14 days and 1 more. Started Aug 2021; status: completed.
02
Drugs
empagliflozin
03
Conditions
nephrolithiasis
Beyond the preview
Go deeper on NCT04911660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04911660.